Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Sagimet Biosciences Inc
SGMT
Healthcare
Biotechnology
Sagimet Biosciences Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. The Company's lead drug candidate, denifanstat, is an oral, once-daily pill and the selective FASN inhibitor...
in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). In addition to MASH, the Company is evaluating denifanstat in acne and in select forms of cancer, disease areas in which dysregulation of fatty acid metabolism also plays a key role. Denifanstat is being tested in a Phase III clinical trial for moderate to severe acne vulgaris, and a Phase III trial for recurrent glioblastoma multiforme (GBM) in combination with bevacizumab.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (NDAQ:SGMT)
New Post
View:
Posts & Comments
Threaded Posts
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Jan 25, 2024 8:58pm
New Press Release - Sagimet Biosciences Announces Pricing of Public Offering of Series A Common Stock
SAN MATEO, Calif., Jan. 25, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (“Sagimet”) (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to target dysfunctional metabolic and fibrotic pathways, today announced the pricing...
read article.
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Jan 23, 2024 5:46pm
New Press Release - Sagimet Biosciences Announces Proposed Public Offering of Series A Common Stock
SAN MATEO, Calif., Jan. 23, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (“Sagimet”) (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to target dysfunctional metabolic and fibrotic pathways, today announced the...
read article.
Level Up Your Trading with BMO InvestorLine’s Enhanced Features
posted Nov 24, 2024 9:00am by
Bank of Montreal
-
|
Features like Multi-Leg Orders, Options Screener, and Strategy Builder will be particularly exciting for traders. They have been designed to be intuitive and user-friendly, regardless of your experience level. Whether you’re a seasoned pro or just starting out, you’ll find these tools easy to navigate and adapt to your investing style. ...read more
(72)
•••
Iseneschal
X
View Profile
View Bullboard History
Post by
Iseneschal
on Jan 22, 2024 1:32pm
SGMT..... Scalped
Cheers !!!!
(72)
•••
Iseneschal
X
View Profile
View Bullboard History
Post by
Iseneschal
on Jan 22, 2024 12:12pm
SGMT....$13.69 crucial support now
It better pick up and vols increase
(72)
•••
Iseneschal
X
View Profile
View Bullboard History
Comment by
Iseneschal
on Jan 22, 2024 12:09pm
RE:SGMT....has to rip over $16 for me to buy
Possible tank...now sub 14
(72)
•••
Iseneschal
X
View Profile
View Bullboard History
Post by
Iseneschal
on Jan 22, 2024 12:01pm
SGMT....draw a line from ~ $6 to where its at now
Thats called a RBL Better stay above or its all over
(72)
•••
Iseneschal
X
View Profile
View Bullboard History
Post by
Iseneschal
on Jan 22, 2024 11:58am
SGMT....has to rip over $16 for me to buy
I see this tanking
(72)
•••
Iseneschal
X
View Profile
View Bullboard History
Post by
Iseneschal
on Jan 22, 2024 11:50am
SGMT....and now for the "Ugly"
Waiting for the gap south?
(72)
•••
Iseneschal
X
View Profile
View Bullboard History
Post by
Iseneschal
on Jan 22, 2024 11:37am
SGMT...hurry up and Kick the bucket ; )
Buh Bye
(72)
•••
Iseneschal
X
View Profile
View Bullboard History
Post by
Iseneschal
on Jan 22, 2024 11:24am
SGMT.....and now for the "sideways action"
til it isn't Range..... $12.20 to $13.50
(72)
•••
Iseneschal
X
View Profile
View Bullboard History
Post by
Iseneschal
on Jan 22, 2024 11:17am
SGMT....30 mins of bliss...then the infamous "rug pull"
Now at N.L.O.D $12.22 What f'king game You've all been had ....again !
(72)
•••
Iseneschal
X
View Profile
View Bullboard History
Post by
Iseneschal
on Jan 22, 2024 11:00am
SGMT...vols are increasing slightly but....
they are all down volume Place ur bets
(72)
•••
Iseneschal
X
View Profile
View Bullboard History
Post by
Iseneschal
on Jan 22, 2024 10:57am
SGMT......Imploding....now at $13.....
With a N.L.O.D of $12.50 Saved all ur a$$e$ again
(72)
•••
Iseneschal
X
View Profile
View Bullboard History
Comment by
Iseneschal
on Jan 22, 2024 10:29am
RE:SGMT...early a.m runner on pos FDA NR
Whoop der id is....just broke $15.90....volume is decreasing....I's say no touching til rally past $16.93 or a tap of the support at $13.72 My targets
(72)
•••
Iseneschal
X
View Profile
View Bullboard History
Post by
Iseneschal
on Jan 22, 2024 10:21am
SGMT...early a.m runner on pos FDA NR
Now in PB mode ...has to hold $15.90 and rally or the next support is $13.72
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >